{"groups":[{"description":"CC-5013 (lenalidomide) plus oral high-dose dexamethasone","id":"FG000","title":"CC-5013/Dex"},{"description":"Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone","id":"FG001","title":"Placebo/Dex"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"18"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"124"}],"type":"Progression of disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"177"},{"groupId":"FG001","numSubjects":"176"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"113"},{"groupId":"FG001","numSubjects":"163"}],"type":"NOT COMPLETED"}],"title":"Up to Unblinding (07 Jun 2005)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"0"}],"type":"Progression of disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"0"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"177"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"171"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Extended Follow-up Cutoff (23 Jul 2008)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Transferred into expanded access study."},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Transferred into RevAssist Program"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Final Follow-up"}],"preAssignmentDetails":"Only subjects in the CC-5013/Dex treatment group participated in the period \"Extended Follow-up Cutoff (23 Jul 2008)\". Data for the period \"Extended Follow-up Cutoff (23 Jul 2008)\" subsumes data for the period \"Up To Unblinding (07 Jun 2005)\".","recruitmentDetails":"Subjects in the Placebo/Dex treatment group did not continue participation beyond the period \"Up To Unblinding (07 Jun 2005\"). Only subjects in the CC-5013/Dex treatment group participated in the period \"Extended Follow-up Cutoff (23 Jul 2008)\"."}